Abstract
The administration of galactosamine to rats produces dose-dependent liver cell injury. A relatively low dose of galactosamine (200 mg/kg) causes a marked fall in UTP with an accompanying inhibition of RNA and protein synthesis. Uridine will reverse the UTP deficiency and the inhibition of RNA and protein synthesis at any time. The administration of a larger dose of galactosamine (400 mg/kg) produces liver cell necrosis within 12 hours. Although the effects on macromolecular synthesis are very similar with the two doses, cell necrosis distinguishes the reaction of the liver to the larger dose from that to the lower. Uridine will also prevent the development of liver cell necrosis, even if given as late as 3 hours after the galactosamine. This was shown by examination of the changes in serum glutamic oxalocetic transaminase levels and by examination of the histologic changes in the livers. Other purines do not have this protective effect; adenine is unable to prevent liver cell necrosis. As the known biochemical effects of the two doses of galactosamine are very similar during the first 3 hours, the protective effect of uridine seems to imply the existence of an as yet unknown lesion distinguishing the reaction of the liver cell to the larger dose of galactosamine. Uridine must prevent the appearance of this lesion or reverse its development.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Decker K., Keppler D., Rudigier J., Domschke W. Cell damage by trapping of biosynthetic intermediates. The role of uracil nucleotides in experimental hepatitis. Hoppe Seylers Z Physiol Chem. 1971 Mar;352(3):412–418. doi: 10.1515/bchm2.1971.352.1.412. [DOI] [PubMed] [Google Scholar]
- FARBER E. ETHIONINE CARCINOGENESIS. Adv Cancer Res. 1963;7:383–474. doi: 10.1016/s0065-230x(08)60986-0. [DOI] [PubMed] [Google Scholar]
- Keppler D. O., Rudigier J. F., Bischoff E., Decker K. F. The trapping of uridine phosphates by D-galactosamine. D-glucosamine, and 2-deoxy-D-galactose. A study on the mechanism of galactosamine hepatitis. Eur J Biochem. 1970 Dec;17(2):246–253. doi: 10.1111/j.1432-1033.1970.tb01160.x. [DOI] [PubMed] [Google Scholar]
- Keppler D., Decker K. Studies on the mechanism of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem. 1969 Sep;10(2):219–225. doi: 10.1111/j.1432-1033.1969.tb00677.x. [DOI] [PubMed] [Google Scholar]
- Keppler D., Decker K. Wirkungsmechanismus von D-Galaktosamin in der leber. Verh Dtsch Ges Inn Med. 1971;77:1182–1185. [PubMed] [Google Scholar]
- Keppler D., Fröhlich J., Reutter W., Wieland O., Decker K. Changes in uridine nucleotides during liver perfusion with D-galactosamine. FEBS Lett. 1969 Aug;4(4):278–280. doi: 10.1016/0014-5793(69)80255-3. [DOI] [PubMed] [Google Scholar]
- Keppler D., Lesch R., Reutter W., Decker K. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol. 1968 Oct;9(2):279–290. doi: 10.1016/0014-4800(68)90042-7. [DOI] [PubMed] [Google Scholar]
- Keppler D., Rudigier J., Reutter W., Lesch R., Decker K. Orotate prevents galactosamine hepatitis. Hoppe Seylers Z Physiol Chem. 1970 Jan;351(1):102–104. [PubMed] [Google Scholar]
- Reutter W., Keppler D., Lesch R., Decker K. Zum Glykoproteidstoffwechsel bei der Galaktosamin-induzierten Hepatitis. Verh Dtsch Ges Inn Med. 1969;75:363–365. [PubMed] [Google Scholar]
- Shinozuka H., Farber J. L., Konishi Y., Anukarahanonta T. D-galactosamine and acute liver cell injury. Fed Proc. 1973 Apr;32(4):1516–1526. [PubMed] [Google Scholar]
- VILLA-TREVINO S., SHULL K. H., FARBER E. The role of adenosine triphosphate deficiency in ethionine-induced inhibition of protein synthesis. J Biol Chem. 1963 May;238:1757–1763. [PubMed] [Google Scholar]
- Villa-Trevino S., Shull K. H., Farber E. The inhibition of liver ribonucleic acid synthesis by ethionine. J Biol Chem. 1966 Oct 25;241(20):4670–4674. [PubMed] [Google Scholar]